Irma M. Puspitasari
Padjadjaran University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Irma M. Puspitasari.
Biological Trace Element Research | 2013
Rizky Abdulah; Herlambang Noerjasin; Leri Septiani; Mutakin; Irma R. Defi; Eka W. Suradji; Irma M. Puspitasari; Melisa I. Barliana; Chiho Yamazaki; Minato Nakazawa; Hiroshi Koyama
Selenium is an essential nutrient for human health, and maternal selenium concentration has been reported to be associated with pregnancy outcome. To further investigate the possible role of selenium (Se) in miscarriage, we conducted a case–control study to evaluate the correlations among selenium status, glutathione peroxidase activity, and spontaneous abortion. A total of 46 subjects with normal pregnancies and 25 subjects with spontaneous abortion were recruited, and their serum selenium concentrations and serum glutathione peroxidase activities were analyzed. The total serum selenium concentrations in subjects with normal pregnancies were significantly higher than those of subjects with spontaneous abortion; however, the glutathione peroxidase activities were similar in both groups. We further separated the subjects into smoking and nonsmoking groups, and the logistic regression analysis suggested that total serum selenium concentration, but not serum glutathione peroxidase activity or smoking, was significantly correlated with the incidence of miscarriage. The present study thus reaffirms that low serum selenium levels are associated with miscarriage and that selenium plays an important role in pregnancy maintenance.
Oncology Letters | 2017
Irma M. Puspitasari; Chiho Yamazaki; Rizky Abdulah; Mirasari Putri; Satomi Kameo; Takashi Nakano; Hiroshi Koyama
The administration of radioprotective compounds is one approach to preventing radiation damage in non-cancerous tissues. Therefore, radioprotective compounds are crucial in clinical radiotherapy. Selenium is a radioprotective compound that has been used in previous clinical studies of radiotherapy. However, evidence regarding the effectiveness of selenium in radiotherapy and the mechanisms underlying the selenium-induced reduction of the side effects of radiotherapy remains insufficient. To further investigate the effectiveness of selenium in radiotherapy, the present study examined the protective effects of sodium selenite supplementation administered prior to X-ray radiation treatment in CHEK-1 non-cancerous human esophageal cells. Sodium selenite supplementation increased glutathione peroxidase 1 (GPx-1) activity in a dose- and time-dependent manner. The sodium selenite dose that induced the highest GPx-1 activity was determined to be 50 nM for 72 h prior to radiotherapy. The half-maximal inhibitory concentration of sodium selenite in CHEK-1 cells was 3.6 µM. Sodium selenite supplementation increased the survival rate of the cells in a dose-dependent manner and enhanced the degree of cell viability at 72 h post-irradiation (P<0.05). Combined treatment with 50 nM sodium selenite and 2 gray (Gy) X-ray irradiation decreased the number of sub-G1 cells from 5.9 to 4.2% (P<0.05) and increased the proportion of G1 cells from 58.8 to 62.1%, compared with 2 Gy X-ray irradiation alone; however, this difference was not statistically significant (P=1.00). Western blot analysis revealed that treatment with 2 Gy X-ray irradiation significantly increased the expression levels of cleaved poly (ADP-ribose) polymerase (PARP; P<0.05). In addition, combined treatment with 50 nM sodium selenite and 2 Gy X-ray irradiation reduced the expression levels of cleaved PARP protein, compared with 2 Gy X-ray irradiation alone; however, this reduction was not statistically significant (P=0.423). These results suggest that 50 nM sodium selenite supplementation administered for 72 h prior to irradiation may protect CHEK-1 cells from irradiation-induced damage by inhibiting irradiation-induced apoptosis. Therefore, sodium selenite is a potential radioprotective compound for non-cancerous cells in clinical radiotherapy.
Biological Trace Element Research | 2018
Rizky Abdulah; Herlambang herlambang; Leri Septiani; Mutakin; Irma R. Defi; Eka W. Suradji; Irma M. Puspitasari; Melisa I. Barliana; Chiho Yamazaki; Minato Nakazawa; Hiroshi Koyama
The original version of this article unfortunately contained a mistake. The name of “Herlambang herlambang” is now corrected in the author group of this article.
Biomedical Reports | 2016
Anas Subarnas; Ajeng Diantini; Rizky Abdulah; Ade Zuhrotun; Patria A. Nugraha; Yuni Elsa Hadisaputri; Irma M. Puspitasari; Chiho Yamazaki; Hiroyuki Kuwano; Hiroshi Koyama
Oncology Letters | 2015
Anas Subarnas; Ajeng Diantini; Rizky Abdulah; Ade Zuhrotun; Yuni Elsa Hadisaputri; Irma M. Puspitasari; Chiho Yamazaki; Hiroyuki Kuwano; Hiroshi Koyama
Biological Trace Element Research | 2018
Novian Febiyanto; Chiho Yamazaki; Satomi Kameo; Dian K. Sari; Irma M. Puspitasari; Deni Kurniadi Sunjaya; Dewi Marhaeni Diah Herawati; Gaga Irawan Nugraha; Toshio Fukuda; Hiroshi Koyama
Indonesian Journal of Clinical Pharmacy | 2012
Irma M. Puspitasari; Soegijardjo Soegijoko
The Indonesian Biomedical Journal | 2018
Steffi Liem; Tina Rostinawati; Ronny Lesmana; Sri Adi Sumiwi; Tiana Milanda; Mutakin Mutakin; Irma M. Puspitasari; Jutti Levita
Indonesian Journal of Clinical Pharmacy | 2018
Rano K. Sinuraya; Dika P. Destiani; Irma M. Puspitasari; Ajeng Diantini
Farmaka | 2018
Hilda Vildayanti; Irma M. Puspitasari; Rano K. Sinuraya